CMP: 990

Wyeth Limited manufactures prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health. The Company is also involved in the development of nutritionals. Wyeth formed the Women's Health Research Institute the only institute in the pharmaceutical industry dedicated solely to research in women's health.

Wyeth is a good buy in mid-cap space. Currently trading at a P/E of 15 with good dividend yields of over 2% in the last 12 months. Minimal liabilities. Revenues have grown steadily from 331 Crores to 640 Crores in the last 5 years. Profits have see-sawed and has grown from 81 Crores to over 160 Crores in the same period. NPM has been strong at 25%. The stock has been strong on chart. Buy for long term gains.